-
Pharma Company Gets FDA Green Light For Next Phase Trial For Tourette Syndrome
Monday, September 30, 2024 - 8:09pm | 469SciSparc Ltd.(NASDAQ:SPRC), a clinical-stage pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has approved its investigational new drug (IND), which enables the company to proceed to Phase IIb clinical trial for its medication to treat Tourette Syndrome (TS). This...
-
Autism CBD Trial On Children Advances As Israeli Company Enrolls First Five Patients
Tuesday, August 20, 2024 - 3:28pm | 501SciSparc Ltd. (NASDAQ:SPRC) announced on Tuesday that the first five patients have been enrolled and dosed into its ongoing clinical trial in children suffering from autism spectrum disorder (ASD) at the Soroka Medical Center in Israel. What Happened The Israeli specialty clinical-stage...
-
Autism CBD Trial Enrolls Children: This Israeli Co. Is Making Headway In New Treatments
Friday, March 8, 2024 - 11:51am | 666SciSparc Ltd. (NASDAQ:SPRC) announced on Friday that it has enrolled the first patient in the company's clinical trial assessing the efficacy and safety of its cannabidiol (CBD) – based drug for the treatment of children with autism spectrum disorder. SCI-210 is a combination of CBD and...
-
Next-Gen Psychedelics Companies SciSparc And Clearmind Collaboration File 3 Patents
Wednesday, February 21, 2024 - 12:12pm | 608The ongoing collaboration between SciSparc Ltd. (NASDAQ:SPRC) and Clearmind Medicine Inc. (NASDAQ:CMND) (CSE:CMND) (FSE: CWY) resulted in the Tuesday filing of three patent applications under the International Patent Cooperation Treaty. SciSparc, a specialty clinical-stage pharmaceutical company...
-
This Company Leads The Way In Cannabinoid Treatment Innovation With New Patent
Tuesday, October 3, 2023 - 11:09am | 358SciSparc Ltd. (NASDAQ: SPRC) announced on Tuesday that the European Patent Office has granted it a new patent. The European Application No. 16786064.2 - titled Combinations of Cannabinoids and N-Acylethanolamines - aligns with the company's objective to increase the safety of cannabinoid...
-
This Pharma Company Is Working With Israeli Medical Center To Research And Treat Autism With CBD
Monday, January 9, 2023 - 5:14pm | 688SciSparc Ltd. (NASDAQ: SPRC), a pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, announced it has signed an agreement with the Soroka University Medical Center, located in Be'er-Sheva, Israel. What's It About? SciSparc,...
-
SciSparc Signs Non-Binding LOI To Sell A 50% Interest In Its Subsidiary That Owns Wellution
Thursday, December 15, 2022 - 11:55am | 378SciSparc Ltd. (NASDAQ: SPRC) has entered into a non-binding letter of intent for the sale of a 50% interest in its wholly owned subsidiary, SciSparc Nutraceuticals Inc., which owns Wellution, to Jeffs' Brands Ltd. (NASDAQ: JFBR), a data-driven e-commerce company operating on Amazon (NASDAQ:...
-
SciSparc And Clearmind Partnership Yields 3rd Patent Application For The Treating Of Obesity And Metabolic Syndromes
Thursday, September 22, 2022 - 12:03pm | 414SciSparc Ltd. (NASDAQ: SPRC) announced that Clearmind Medicine Inc. (OTCPK:CMNDF) (CSE:CMND) (FSE:CWY0), has filed a provisional patent application related to metabolic syndromes including obesity, regarding the company's collaboration with Clearmind. The patent application is the third of the...
-
SciSparc To Acquire One Of Top Sellers Of Food Supplements, Cosmetics And Hemp-Based Products On Amazon
Wednesday, September 14, 2022 - 9:14am | 686SciSparc Ltd. (NASDAQ: SPRC) signed a definitive agreement with Merhavit M.R.M Holding and Management Ltd (“M.R.M”), to acquire its rights to purchase, Wellution, an Amazon.com (NASDAQ: AMZN) Marketplace account, American food supplements and cosmetics brand and trademark. The company...
-
SciSparc Awaiting Approval For Phase IIb Study Of Its Dronabinol Based Drug For Treatment Of Tourette Syndrome
Wednesday, June 29, 2022 - 10:26am | 441SciSparc Ltd. (NASDAQ: SPRC), a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, has successfully completed the development of its top-tier drug candidate SCI-110 to be used in its upcoming multinational,...
-
SciSparc & Clearmind Medicine Team Up On Patent For Psychedelic Combination To Treat Cocaine Addiction
Thursday, June 2, 2022 - 11:28am | 437SciSparc Ltd. (NASDAQ: SPRC) collaboration with Clearmind Medicine Inc. (OTCPK:CMNDF) (CSE:CMND) (FSE:CWY0) resulted in the filing of a provisional patent application related to treating cocaine addiction. The patent application refers to the proprietary combination of SciSparc's CannAmide with...